

INNOVATING THROUGH PARTNERSHIPS

Panel Discussion

October 29, 2018

DCVMN, Kunming



How can partnerships help to accelerate time to market for high impact vaccines ?

Panel Members



Mauricio Zuma Medeiros, General Director, BioManguinhos



Steve Davis, President & CEO, PATH



Mariangela Simao, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals, WHO



Patrick Tippoo, Head of Science & Innovation, The Biovac Institute




Harish Iyer, Senior Advisor, Life Sciences Partnerships, BMGF




Context: We can save an additional 3.3M lives through the development of innovative vaccines¹ , but the path to market is getting slower and more challenging...

3.5M lives remain to be saved through vaccine innovation...




... but success rates from Phase 1 to launch have decreased...

Avg success rates from Phase 1 to launch (%)



... while time to market has increased


Avg time between Phase 1 and launch (yrs)



... Hence no company or NGO alone will likely be able to carry the burden of vaccine innovation for LMICs alone


Launching innovative vaccines is costly ...

Average cost of development per phase (\$M)




... and time-consuming...

Average time per phase (yrs)



...with a low probability of success, especially for unprecedented vaccines

Probability of success per phase (%)



Phase 3 Phase 2 Phase 1 Preclinical

How can partnerships help to accelerate time to market for high impact vaccines?